Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Accumulation of 11c-erlotinib in tumors before and after treatment with erlotinib
Accumulation of 11c-erlotinib in tumors will be correlated to PFS on erlotinib treatment.
From date of inclusion until the date of first documented progression on the erlotinib treatment or date of death, whichever came first, assessed up to 30 months
Peter Meldgaard, Ph.D MD
Aarhus University Hospital
Denmark: The Regional Committee on Biomedical Research Ethics